Advanced searches left 3/3

Carcinoma In Situ - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 September 2022

* If you want to update the article please login/register

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

In preventing the occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral duct carcinoma in situ in women with human epidermal growth factor receptor 2 -positive DCIS resected by lumpectomy, it is important to determine the value of trastuzumab given during radiation therapy in comparison to RT alone in preventing future occurrence of ipsilateral breast cancer recurrence, resected by lumpectomy in women with re retilateral breast cancer re rertie rence, or re ductal carcinoma in women with re retu re retu re retue re retu re rection re reticular re retilateral re o reticular hemo reticular obstab rec versus reticular reti In prolonging invasive or DCIS disease-free survival, DCIS disease-free survival is the result of a tuzumab administered during RT in comparison to RT alone. -DCIS Determine the benefit of trastuzumab administered during RT relative to RT alone in raising the risk of contralateral invasive or DCIS breast cancer in women over RT. In the cMYC non-amplified subset, the benefit of trastuzumab added to RT will be much higher in v-myc avian myelocytomatosis viral oncogene homolog -amplified tumors than in the cMYC non-amplified subset. Determine whether the benefit of trastuzumab in RT will be less in tumors with mutations in the phosphatidylinositol 3 kinase gene than in tumors with PI3 kinase gene mutations than in tumors without a kinase gene mutation.

Source link: https://clinicaltrials.gov/ct2/show/NCT00769379


Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A Randomized, Phase IIb, Window of Opportunity Presurgical Trial.

In the first 14 participants assigned to the experimental therapy arm, there was a way to determine the effectiveness of the experimental intervention based on the frequency of occurrence of a dose limiting toxicity in the first 14 participants. Evaluate the difference between the active therapy and the control group, depending on the condition and the control group, with cancer adjacent ductal carcinoma in situ, if present, or intraepithelial neoplasia. To investigate the effect of intervention on the expression of PP2A-GSK3beta-MCL-1 axis in pre-treatment cancer tissue samples, as well as in post-treatment cancer tissue samples. Cell death by immunohistochemistry for M30 in post-treatment cancer samples from armies was determined by the researchers. To determine the difference between phosphorylated S6 and IHC in post-treatment cancer samples from both arms. According to different doses of metformin hydrochloride extended release, it's difficult to determine the area under the curve of glucose levels in arm and within the experimental arm. Patients fast for >= 16 hours per night and use the continuous glucose monitoring device for 4-6 weeks, according to ARM I. On days 0 and 10, patients also receive nutritional counseling sessions. Patients are also treated with metformin hydrochloride extended release orally every day until the day of surgery, beginning week 2. Patients maintain their regular eating habits and use the continuous glucose monitoring device for 4-6 weeks. Patients underwent blood testing at baseline and during the final study visit, as well as the collection of tissue at the time of surgery.

Source link: https://clinicaltrials.gov/ct2/show/NCT05023967


Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma

Breast cancer and/or HGSC development is a risk for breast cancer and/or HGSC development in women with germ line mutations in the BRCA1 and BRCA2 gene or a family history of epithelial ovarian cancer. In women with BRCA1 gene mutations, the lifetime risk of ovarian cancer is 35 to 45 percent, and 13 to 23 percent in those with BRCA2 mutations. As for today, risk reduction in HGSC in high risk women is the most feasible option for lowering the risk of HGSC. About 80% of these neoplasms are found in the ampullar portion of the fallopian tube, with 4 to 17 percent of women with a higher risk of HGSC who underwent rrbSO. STIC cells can be found in the uterine cavity after ovulation, according to the physiological function of the tube's ciliated lining, transporting the egg into the uterine cavity after ovulation, thus making it likely that exfoliated cells from STICs can be present in the uterine cavity. Urine lavages were collected before a surgical intervention for suspected ovarian cancer cells were removed and discovered in the lavages of the uterine cavity, at Notre Dame University Leuven, Belgium, for the demonstration of principle that tumor cells from ovarian cancer are shed and can be found in the lavages of the uterine cavity. The presence of these genetic abnormalities was determined in lavage samples using digital droplet PCR. Aim of the study: The current research investigate investigates whether exfoliated cells from STICs are transported into the uterine cavity via the fallopian tube, and whether it is possible to detect such cells in the lavage fluid from the uterine cavity and proximal fallopian tubes. Methods: The investigators will investigate 20 lavage samples and their 20 corresponding STIC-positive tissue samples in women who opt for rrBSO due to an elevated risk of HGSC and without a tradition of tubal occlusion for sterilization.

Source link: https://clinicaltrials.gov/ct2/show/NCT02039388

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions